Clinical Professor in Oncology, University Hospital of Southern Denmark, Esbjerg, Denmark.
Joined December 2019
- Tweets 168
- Following 240
- Followers 238
- Likes 117
16 Photos and videos
31 Jul 2023
Well-written and insightful paper every oncologist and clinician with frontline clinical workload should read - before burnout
Oncology is a demanding profession, asking a great amount of those practicing in the field. Oncology clinicians can set boundaries while still meeting ethical practice standards. Setting boundaries may ultimately allow clinicians to be more present & engaged while working, have more satisfaction with their work, & maintain personal well-being. Some great suggestions in this table & article ascopubs.org/doi/full/10.120…
1
4
279
Frede Donskov retweeted
5 Jun 2023
Updated IO combo table after #ASCO2023 IO/TKI presentations. VEGF tx provides early disease control while Ipi provides durability. We need a way to harness the benefits of both approaches. @montypal @DrChoueiri @tompowles1 @motzermd @HHammersMD
2
96
245
39,265
20 Mar 2023
Any suggestions for a training scheme @HowardGurney ?
19 Mar 2023
We need comprehensive training schemes for trial coordinators and move beyond the current apprentice scheme. Experienced trial coordinators are in short supply and we need to stop poaching each others
68
Frede Donskov retweeted
19 Dec 2022
Flere kvitter, når prisen på cigaretter ryger i vejret. Men prisen skal hoppe, så det kan mærkes - ellers har det ingen effekt. Så hjælp @sophieloehde og sundheden, @JeppeBruus:
Sæt prisen højt op, så vi kan få en #røgfrifremtid
#dkpol #sundpol
altinget.dk/sundhed/artikel/…
7
1
34
7,789
Frede Donskov retweeted
13 Nov 2022
I thought only astronauts, bond villains and tech billionaires appeared in TIME magazine. Some people are all 3 but David McDermott is certainly none of the above and still made it! @Uromigos gbr01.safelinks.protection.o…
12
66
Frede Donskov retweeted
30 Oct 2022
Cytoreductive nephrectomy associated with longer OS in patients with #mRCC treated with immune checkpoint inhibitor (ICI) therapy in any line of therapy. A multicenter retrospective cohort study of 367 patients (CN ST 232, ST alone 135). sciencedirect.com/science/ar…
5
44
157
Frede Donskov retweeted
26 Sep 2022
The new Prime Minister of Italy.
Wow. x.com/FuryOriental/status/15…
11,194
59,429
237,158
23 Sep 2022
Very excited to see our work on molecular analysis in Clear Cell & Non-Clear Cell Real-World #Renal Cell Carcinoma just published in @actaoncol
Thanks to great collaborative effort w co-authors
doi.org/10.1080/0284186X.202…
@OncoAlert @DrChoueiri @montypal @brian_rini @TSteiniche
2
8
Frede Donskov retweeted
18 Sep 2022
About the smile: the standing ovation also meant that people saw what I knew: behind every one of these bars is a patient. I know every name and have seen almost everyone. I know their stories and their children. And I believe many are cured because of this. #ESMO22 #ChalabiPlot
34
250
1,847
14 Sep 2022
Awesome discussion!
12 Sep 2022
Hello to those waking up on the west coast! Had a chance to discuss @DrChoueiri's outstanding presentation of #COSMIC313 at #ESMO22 in the presidential session. Here's a quick synopsis. 1st, what an AMAZING mtg this has been for #kidneycancer (slide credit: @ZeynepZengin) (1/10)
Frede Donskov retweeted
11 Sep 2022
A waterfall plot or a tidal wave 🌊???? 🤩 😯
99% pathologic response with nivo/ipi in dMMR CRC and NO disease recurrences!!
#ESMO22 @myESMO @MyriamChalabi
12
125
564
Frede Donskov retweeted
11 Sep 2022
#ESMO22 Presidential symposium - adjuvant nivo/ipi in #RCC by @motzermd:
- 15% pT2a g3/4, pT2b
- 5% sarcomatoid (pdl1 status pending)
- placebo arm 24-mos DFS rate 74% (note 67% in KN-564)
- 1 in 3 d/c due to drug tox
@DrChoueiri @montypal @neerajaiims @BradMcG04 @OncoAlert
30
71
10 Sep 2022
Great summary @montypal on adjuvant therapy in #renalcellcarcinoma
10 Sep 2022
Grateful to @TheLancet for allowing us to publish our experience with #adjuvant #atezolizumab (#IMmotion010) simultaneous w the presentation by #AxelBex at #ESMO22. It's interesting to envision how this data impacts current landscape (link below): (1/10) thelancet.com/journals/lance…
1
1
3
Frede Donskov retweeted
1 Sep 2022
2
1
16
Frede Donskov retweeted
30 Aug 2022
Our 30-month #KYN564 adjuvant RCC trial is published @TheLancetOncol —led by @tompowles1, presented #GU22 @ASCO —Note HR 0.63 improved from 0.68, all subgroups HR<1, AND if we remove M1NED/N /T4=> HR 0.68. Still significant/clinically relevant @OncoAlert
sciencedirect.com/science/ar…
4
82
214
Frede Donskov retweeted
21 Jul 2022
Our @IMDConline paper outlining #cabozantinib activity post #immunotherapy combination treatment in #kcsm #kidneycancer is out in @ElsevierConnect Clinical Genitourinary Cancers..1/6🧵
clinical-genitourinary-cance…
2
9
20
13 Apr 2022
Important study published. Leibovich and GRANT validated in ccRCC and non-ccRCC nationwide #kidneycancer cohort. Leibovich outperformed GRANT in predicting recurrence-free survival and should remain
standard approach to risk stratify patients. @oncoalert
doi.org/10.1111/iju.14859
11 Apr 2022
Do we have a Litmus test to predict survival in localized kidney cancer?
🔸7653 patients: GRade, Age, Nodes, and Tumor score (GRANT) 🇩🇰
🔸Leibovich score outperformed the GRANT regarding RFS
@FDonskov @OncoAlert @Uroweb @urotoday @NessnAzawi @KidneyCancer
onlinelibrary.wiley.com/doi/…
3
10
8 Apr 2022
Stong 5-yr data just published @KidneyCancer
7 Apr 2022
CheckMate 214
🔸Durable-long-term efficacy with Nivo-IPI
🔸mFU 67.7 months
🔸mOS: 55.7 months (48% @5Y)
🔸After 3 years the probability of remaining alive for an additional 2 years ↗️ with NIVO IPI regardless of IMDC
@JournalCancer @OncoAlert @DrChoueiri
acsjournals.onlinelibrary.wi…
4
Frede Donskov retweeted
7 Apr 2022
CheckMate 214
🔸Durable-long-term efficacy with Nivo-IPI
🔸mFU 67.7 months
🔸mOS: 55.7 months (48% @5Y)
🔸After 3 years the probability of remaining alive for an additional 2 years ↗️ with NIVO IPI regardless of IMDC
@JournalCancer @OncoAlert @DrChoueiri
acsjournals.onlinelibrary.wi…
29
52